The Opportunity: Addressing a Critical Preparedness Gap |
Chlorine is one of the most widely used industrial chemicals in the world and is a leading cause of toxic inhalation exposure. Accidental releases, transportation incidents, industrial accidents, and intentional misuse can result in serious lung injury, respiratory distress, and death. Despite the ongoing risk, there is currently no FDA-approved drug specifically designed to treat chlorine-induced lung injury. Current care relies largely on supportive measures that do not directly address the underlying damage.
The Technology & Current Status
MIDD0301 is an advanced respiratory therapeutic that targets GABA(A) receptors outside the central nervous system. Originally developed for respiratory diseases, the compound has demonstrated bronchodilatory and anti-inflammatory activity in preclinical studies and advanced through safety and formulation development.
Recent studies demonstrated improved outcomes following chlorine exposure in animal models, supporting its potential use for acute chemical inhalation injury. Researchers are evaluating delivery approaches for emergency response.
Initial Target Applications and Markets
Potential customers include emergency preparedness agencies, the Strategic National Stockpile, military organizations, first responders, healthcare systems, and organizations involved in the production and transport of hazardous chemicals.